Faecal Microbiota Transplantation for Liver Cirrhosis (CHiFT)
Faecal Microbiota Transplantation to Prevent Complications, Progression and Mortality of Liver Cirrhosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Karen Louise Thomsen, PhD
- Phone Number: +4526949260
- Email: karethom@rm.dk
Study Contact Backup
- Name: Sidsel Støy, PhD
- Phone Number: +4561664565
- Email: sidsel.stoy@clin.au.dk
Study Locations
-
-
-
Aarhus, Denmark, 8200
- Recruiting
- Department of Hepatology and Gastroenterology, Aarhus University Hospital
-
Contact:
- Karen Louise Thomsen, PhD
- Phone Number: +4526949260
- Email: karethom@rm.dk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-75 years
- Liver cirrhosis with Child-Pugh ≤ 12
- Acute decompensation requiring intervention (ascites, gastrointestinal bleeding, infections leading to progressive liver failure, overthepatic encephalopathy, alcoholic hepatitis)
Exclusion Criteria:
- More than one organ failure defined by CLIF-SOFA score
- Untreated malignancy apart from non-melanoma skin cancer
- Untreated viral hepatitis
- HIV
- Inflammatory bowel disease
- Celiac disease
- Clostridioides Difficile infection
- Pregnancy
- Unable to participate based on medical judgement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Faecal microbiota transplantation
The patients will receive three applications of FMT consisting of 50 g cryopreserved, homogenized faeces from healthy donors.
The faecal material will be dispensed into double-coated, acid-resistant enterocapsules or cryobags.
Faeces will be screened according to international guidelines.
|
All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
Other Names:
|
|
Placebo Comparator: Placebo
The placebo products is produced from a suspension of glycerol, saline and food colouring and cannot be distinguished from the active FMT products.
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to death or new episode of acute decompensation requiring intervention in FMT versus placebo-treated patients.
Time Frame: 1 year
|
Using data from the patient journals, we will be able to examine the exact time to event in each of the patients.
To compare the two groups, hazard ratios will be calculated.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to death or new episode of acute decompensation requiring intervention in FMT versus placebo-treated patients at 3 months and 6 months of follow-up.
Time Frame: 3 months, 6 months
|
Using data from the patient journals, we will be able to examine the exact time to event in each of the patients.
To compare the two groups, hazard ratios will be calculated.
|
3 months, 6 months
|
|
Change in disease severity in FMT- versus placebo-treated patients.
Time Frame: 3 months, 6 months, 1 year.
|
The disease severity will be measured with Model for Endstage Liver Disease (MELD) (range 6-40).
A high score reflects poor prognosis.
|
3 months, 6 months, 1 year.
|
|
Change in disease severity in FMT- versus placebo-treated patients.
Time Frame: 3 months, 6 months, 1 year.
|
The disease severity will be measured with Child-Pugh score (range 5-15).
A high score reflects poor prognosis.
|
3 months, 6 months, 1 year.
|
|
Change in disease severity in FMT- versus placebo-treated patients.
Time Frame: 3 months, 6 months, 1 year.
|
The disease severity will be measured with CliF-C Acute decompensation scores (range 0-18).
A high score reflects poor prognosis.
|
3 months, 6 months, 1 year.
|
|
Change in metabolic liver function in FMT- versus placebo-treated patients.
Time Frame: 3 months, 6 months, 1 year.
|
The metabolic liver function will be measured by the aminopyrine breath test
|
3 months, 6 months, 1 year.
|
|
Change in liver stiffness in FMT- versus placebo-treated patients.
Time Frame: 3 months, 6 months, 1 year.
|
Liver stiffness will be measured by liver elastography.
|
3 months, 6 months, 1 year.
|
|
Change in the Liver Frailty Index in FMT- versus placebo-treated patients.
Time Frame: 3 months, 6 months, 1 year.
|
The Liver Frailty index (grip strength, chair stands, and balance testing) will be calculated and the index will be compared between the treatment groups.
A higher LFI indicates more frailty.
|
3 months, 6 months, 1 year.
|
|
Change in body composition in FMT- versus placebo-treated patients.
Time Frame: 3 months, 6 months, 1 year.
|
Body composition will be measured by bioimpedance.
|
3 months, 6 months, 1 year.
|
|
Change in cognitive function in FMT- versus placebo-treated patients.
Time Frame: 3 months, 6 months, 1 year.
|
The cognitive function will be measured with the portosystemic encephalopathy syndrome test.
|
3 months, 6 months, 1 year.
|
|
Number of new decompensations and deaths during follow-up in the FMT versus the placebo-treated patients.
Time Frame: 1 year
|
Incidence rates will be compared between the groups.
|
1 year
|
|
Time to death in FMT versus placebo-treated patients. -treated patients at 3 months and 6 months of follow-up.
Time Frame: 1 year, 6 months, 3 months
|
Using data from the patient journals, we will be able to examine the exact time to event in each of the patients.
To compare the two groups, hazard ratios will be calculated.
|
1 year, 6 months, 3 months
|
|
Change in gut microbiota beta-diversity (Bray-Curtis index) during one year in FMT versus placebo-treated patients by shotgun metagenomic sequencing.
Time Frame: 1 year, 6 months, 3 months
|
In stool and saliva samples collected before and at 5 time points following the intervention, we will measure the gut microbiota composition.
|
1 year, 6 months, 3 months
|
|
Change in plasma concentration of gut translocation markers; lipopolysaccharide binding protein, soluble CD14, fatty acid binding protein 1 during one year in FMT versus placebo-treated patients by ELISA.
Time Frame: 1 year, 6 months, 3 months
|
In blood samples collected at baseline and at follow-up visits, we will measure these plasma proteins by ELISA.
|
1 year, 6 months, 3 months
|
|
Change in plasma and stool concentration of pro- and antiinflammatory cytokines; IL-6, IL-1beta, TNF-alpha, IL-8, IL-10 in response to the intervention by luminex.
Time Frame: 1 year, 6 months, 3 months
|
In blood and stool samples collected at baseline and at follow-up visits, we will measure these plasma proteins by luminex.
|
1 year, 6 months, 3 months
|
|
Change in cognitive function as measured by continuous reaction time in FMT- versus placebo-treated patients.
Time Frame: 3 months, 6 months, 1 year.
|
The cognitive function will be measured with continuous reaction time.
|
3 months, 6 months, 1 year.
|
|
Change in quality adjusted life years (QALY´s) to evalute health care related costs in FMT- versus placebo-treated patients
Time Frame: 1 year
|
By using the quality-of-life questionnaire (EQ-5D-5L) a single index will be calculated and used to calculate QALY's.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1-10-72-302-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.